Languages

Accessibility

  • Change text size

    • Normal Text
    • Medium Text
    • Large Text

  • Contrast

    • Black&white
    • High
    • Normal

  • Display

    • Cursor White
    • Cursor Black
    • Highlighting

  •  

Languages

Accessibility

  • Change text size

    • Normal Text
    • Medium Text
    • Large Text

  • Contrast

    • Black&white
    • High
    • Normal

  • Display

    • Cursor White
    • Cursor Black
    • Highlighting

  •  
03 October 2013

Yigal Arnon & Co. in cooperation with IATI, invite Hi-Tech & Life Science Start-ups to join us in the event: “The Ins-and-Outs of the Due Diligence Process in Investment Transactions”

Yigal Arnon & Co. in cooperation with IATI (Israel Advanced Technology Industries) invite Hi-Tech & Life Science Start-ups to join us in the event: “The Ins-and-Outs of the Due Diligence Process in Investment Transactions”, October 23, 2013, Yigal Arnon & Co. offices.

Yigal Arnon & Co. in cooperation with IATI (Israel Advanced Technology Industries) invite Hi-Tech & Life Science Start-ups to join us in the event: “The Ins-and-Outs of the Due Diligence Process in Investment Transactions”, October 23, 2013, Yigal Arnon & Co. offices.


13 August 2013

Yigal Arnon & Co. represents Johnson & Johnson, Takeda Pharmaceuticals and OrbiMed, to establish a Biotech Incubator

Advocates Barry Levenfeld, Harry Kirsh, Yuval Shalhevet, Zohar Nevo and Noam Enk represents the winning bidding consortium, consisting of Johnson & Johnson, Takeda Pharmaceuticals (the first Japanese Pharmaceutical Company to invest in Israel) and the healthcare fund OrbiMed Israel, for the establishment of an OCS-supported biotechnological incubator intended to encourage the creation and support of pharmaceutical and medical device companies.

Advocates Barry Levenfeld, Harry Kirsh, Yuval Shalhevet, Zohar Nevo and Noam Enk represents the winning bidding consortium, consisting of Johnson & Johnson, Takeda Pharmaceuticals (the first Japanese Pharmaceutical Company to invest in Israel) and the healthcare fund OrbiMed Israel, for the establishment of an OCS-supported biotechnological incubator intended to encourage the creation and support of pharmaceutical and medical device companies.


28 May 2013

Yigal Arnon & Co. represented Aegis as the sole book-running manager for Alcobra Ltd.’s initial public offering on Nasdaq.

Advs. Barry Levenfeld, Eric Spindel, Avigail Frisch and Noam Enk represented Aegis for Alcobra Ltd.'s initial public offering on Nasdaq. Alcobra Ltd., headquartered in Israel, is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug to treat Attention Deficit Hyperactivity Disorder.
 

Advs. Barry Levenfeld, Eric Spindel, Avigail Frisch and Noam Enk represented Aegis for Alcobra Ltd.'s initial public offering on Nasdaq. Alcobra Ltd., headquartered in Israel, is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug to treat Attention Deficit Hyperactivity Disorder.
 


04 November 2012

Yigal Arnon & Co. represented Stryker in purchasing Surpass Medical for $135 million

Advocates Barry Levenfeld, Ben Sandler, Harry Kirsh, Avigail Frisch and Zohar Nevo represented Stryker, an U.S.-based leader in worldwide orthopedic medical technology in the acquisition  of the Israeli company Surpass Medical, which develops and commercializes next-generation flow diversion technology to treat brain aneurysms, for $135 million.

Advocates Barry Levenfeld, Ben Sandler, Harry Kirsh, Avigail Frisch and Zohar Nevo represented Stryker, an U.S.-based leader in worldwide orthopedic medical technology in the acquisition  of the Israeli company Surpass Medical, which develops and commercializes next-generation flow diversion technology to treat brain aneurysms, for $135 million.


23 April 2012

Yigal Arnon & Co., BDO and The Luzzatto Group co-hosted the 7th High-tech Conference, April 23, 2012

Yigal Arnon & Co., BDO and The Luzzatto Group continued the tradition and cooperated again in the 7th High-tech Conference that took place on April 23, 2012, at the Dan Hotel in Tel Aviv. Adv. Barry Levenfeld lectured on The Next Big Exit:  Preparing Your Hi Tech Company for IPO or Acquisition.  
Yigal Arnon & Co., BDO and The Luzzatto Group continued the tradition and cooperated again in the 7th High-tech Conference that took place on April 23, 2012, at the Dan Hotel in Tel Aviv.
Adv. Barry Levenfeld lectured on The Next Big Exit:  Preparing Your Hi Tech Company for IPO or Acquisition.

 


26 January 2011

Barry Levenfeld chaired session on M&A at International Bar Association Conference

Barry Levenfeld chaired the session on Merger and Acquisitions of Life Science and Technology Companies in the International Bar Association Conference on "The Globalization of Knowledge-Based Industries" that took place in Tel Aviv, at the Hilton Hotel, on February 9-11. 

Barry Levenfeld chaired the session on Merger and Acquisitions of Life Science and Technology Companies in the International Bar Association Conference on "The Globalization of Knowledge-Based Industries" that took place in Tel Aviv, at the Hilton Hotel, on February 9-11. 


Rankings

Subscribe for updates and news

This site uses Cookies